Defender Pharmaceuticals Receives Complete Response Letter from the U.S. Food and Drug Administration for its Intranasal Scopolamine (DPI-386) New Drug Application for the Prevention of Nausea and Vomiting Induced by Motion in Adults

ST. LOUIS, MO—(BUSINESS WIRE)—Jan. 30, 2024—Defender Pharmaceuticals, Inc. (the“Company” or“Defender”), a privately held life sciences company based in St. Louis, today announced that the U.S. Food and...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news